Welcome to our dedicated page for Kezar Life Sciences news (Ticker: KZR), a resource for investors and traders seeking the latest updates and insights on Kezar Life Sciences stock.
Kezar Life Sciences (KZR) is a clinical-stage biotechnology company pioneering novel small molecule therapeutics for autoimmune disorders and oncology. This page provides authoritative updates on corporate developments, clinical research, and strategic initiatives essential for informed decision-making.
Access real-time updates on KZR-616 clinical trials, regulatory milestones, and scientific advancements alongside financial disclosures and partnership announcements. Our curated news collection serves investors, researchers, and healthcare professionals seeking comprehensive insights into the company’s progress.
Key coverage areas include immunoproteasome inhibitor developments, trial phase updates, intellectual property news, and collaborative research efforts. All content undergoes rigorous verification to ensure alignment with SEC filings and peer-reviewed publications.
Bookmark this page for streamlined access to KZR’s latest material events. Combine our news monitoring with SEC filings and medical journals for complete due diligence.
Kezar Life Sciences (KZR) announced positive topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for autoimmune hepatitis (AIH) treatment. In the trial's key findings, 36% of zetomipzomib-treated patients achieved complete biochemical response with significant steroid reduction, compared to 0% in the placebo group.
The study demonstrated that in the intention-to-treat population, 31% of zetomipzomib patients achieved complete response and steroid taper, versus one placebo patient. Notably, the median response duration was 27.6 weeks, with no disease flares reported in responding patients.
Financial highlights as of December 31, 2024:
- Cash position: $132.2 million
- R&D expenses decreased to $65.7 million from $85.7 million in 2023
- G&A expenses reduced to $23.4 million from $26.5 million in 2023
- Net loss: $83.7 million ($11.49 per share)
Kezar Life Sciences (Nasdaq: KZR) has announced an upcoming presentation of topline results from their PORTOLA Phase 2a trial evaluating zetomipzomib for treating autoimmune hepatitis (AIH). The presentation is scheduled for March 25, 2025, at 8:00 a.m. ET.
The PORTOLA trial is a placebo-controlled, randomized, double-blind Phase 2a clinical trial assessing the efficacy and safety of zetomipzomib in AIH patients. The event will feature presentations from key investigators including Dr. Craig Lammert from Indiana University School of Medicine and Dr. Gideon Hirschfield from Toronto General Hospital, followed by a Q&A session.
The presentation will be accessible via live audio webcast with slides, and a replay will be available for 90 days afterward on the company's website.
Kezar Life Sciences (Nasdaq: KZR) announced a virtual Key Opinion Leader (KOL) event hosted by William Blair on February 27, 2025, at 4:00 p.m. ET. The event will focus on zetomipzomib clinical development in autoimmune hepatitis (AIH) and provide a safety update from the PALIZADE Phase 2b trial for lupus nephritis (LN).
Dr. Aparna Goel from Stanford University will discuss AIH patient burden, current treatments, and future treatment landscape. The company will present an overview of the PORTOLA Phase 2a trial of zetomipzomib in AIH patients, with topline data expected in H1 2025. Additionally, a safety update will be provided for the PALIZADE Phase 2b trial, which was discontinued and unblinded in October 2024.
Kezar Life Sciences reported Q3 2024 financial results and provided updates on its clinical trials. The company's cash position stood at $148.4 million as of September 30, 2024. The PORTOLA Phase 2a trial for autoimmune hepatitis continues with topline data expected in H1 2025, while the PALIZADE Phase 2b trial for lupus nephritis was terminated following safety concerns. The company reported a net loss of $20.3 million ($2.78 per share) for Q3 2024. R&D expenses decreased to $16.2 million from $23.7 million year-over-year, while G&A expenses reduced to $5.7 million from $8.8 million.
Kezar Life Sciences (Nasdaq: KZR) announced a 1-for-10 reverse stock split effective October 29, 2024, at 5:00 p.m. Eastern Time. The company's stock will begin trading on a post-split basis on October 30, 2024. This move aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The split will reduce outstanding shares from 72,962,220 to 7,296,222. Stockholders' positions will be automatically adjusted, with fractional shares rounded up to the nearest whole number. The split was approved by stockholders on June 18, 2024, with the final ratio approved by the Board on September 23, 2024.
Kezar Life Sciences (Nasdaq: KZR) has unanimously rejected an unsolicited proposal from Concentra Biosciences to acquire all outstanding shares for $1.10 per share plus a contingent value right. The Board concluded that the offer substantially undervalues the company and fails to reflect the potential of zetomipzomib. In response to Concentra's rapid accumulation of 9.9% of Kezar's stock, the Board has adopted a duration stockholder rights plan.
The Rights Plan aims to protect stockholders' long-term value and reduce the likelihood of control gain through open market accumulation without paying an appropriate premium. It allows one preferred share purchase right for each outstanding common share as of October 28, 2024. Rights become exercisable if an entity acquires 10% or more of Kezar's stock (15% for passive institutional investors). The plan expires on October 17, 2025, unless redeemed or exchanged earlier.
Kezar Life Sciences (Nasdaq: KZR) announced key clinical development updates for its zetomipzomib trials. The PORTOLA Phase 2a trial in autoimmune hepatitis (AIH) will continue without modification following a positive safety review by the Independent Data Monitoring Committee (IDMC). Topline data is expected in the first half of 2025. However, the company has decided to discontinue the PALIZADE Phase 2b trial in lupus nephritis (LN) patients after it was placed on clinical hold due to four Grade 5 (fatal) serious adverse events. Kezar will now focus its resources on developing zetomipzomib for AIH. The company's unaudited cash position is approximately $148 million as of September 30, 2024.
Kezar Life Sciences (Nasdaq: KZR) has received an unsolicited, non-binding acquisition proposal from Concentra Biosciences, The offer includes:
- Cash consideration of $1.10 per share
- A contingent value right for 80% of net proceeds from any out-license or disposition of Kezar's development programs or intellectual property
Tang Capital Management, , the controlling stockholder of Concentra, owns approximately 9.9% of Kezar's outstanding common stock. Kezar's Board and management team will evaluate the proposal to determine the best course of action for the company and its stockholders. No immediate action is required from Kezar stockholders.
Kezar Life Sciences (Nasdaq: KZR) announced that the FDA has placed a clinical hold on the zetomipzomib Investigational New Drug (IND) application for the treatment of lupus nephritis (LN). This follows Kezar's voluntary suspension of enrollment and dosing in its Phase 2b PALIZADE clinical trial of zetomipzomib in LN patients, based on the recommendation of the trial's Independent Data Monitoring Committee (IDMC).
The IDMC's recommendation came after reviewing emerging safety data, including four Grade 5 (fatal) serious adverse events (SAEs) in patients enrolled in the Philippines and Argentina. The FDA will provide an official clinical hold letter within 30 days. Kezar's CEO, Chris Kirk, emphasized their commitment to patient safety and ongoing investigation of these cases.
The zetomipzomib IND for autoimmune hepatitis remains unaffected, with the Phase 2a PORTOLA clinical trial continuing without any Grade 4 or 5 SAEs observed to date.
Kezar Life Sciences (Nasdaq: KZR) has voluntarily ceased enrollment and dosing in its Phase 2b PALIZADE trial of zetomipzomib for active lupus nephritis. This decision follows the recommendation of the Independent Data Monitoring Committee after reviewing emerging safety data, including four Grade 5 (fatal) serious adverse events in patients from the Philippines and Argentina. Three fatalities showed a common pattern of symptoms and proximity to dosing. Kezar remains blinded to which patients were on zetomipzomib or placebo.
The ongoing Phase 2a PORTOLA trial for autoimmune hepatitis continues, with no Grade 4 or 5 SAEs observed. Kezar is evaluating the data to determine next steps and potential risk mitigation strategies. The company has notified study investigators and is informing regulatory authorities. No formal FDA clinical hold has been issued yet.
